PSTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Poseida Therapeutics's share price for the quarter that ended in Sep. 2024 was $2.86. Poseida Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 97.4 Mil. Therefore, Poseida Therapeutics's market cap for the quarter that ended in Sep. 2024 was $278.6 Mil.
Poseida Therapeutics's quarterly market cap declined from Mar. 2024 ($308.8 Mil) to Jun. 2024 ($283.5 Mil) and declined from Jun. 2024 ($283.5 Mil) to Sep. 2024 ($278.6 Mil).
Poseida Therapeutics's annual market cap increased from Dec. 2021 ($425.8 Mil) to Dec. 2022 ($455.6 Mil) but then declined from Dec. 2022 ($455.6 Mil) to Dec. 2023 ($321.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Poseida Therapeutics's Enterprise Value for Today is $777.8 Mil.
The historical data trend for Poseida Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poseida Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Market Cap | Get a 7-Day Free Trial | - | 678.62 | 425.79 | 455.61 | 321.34 |
Poseida Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
227.47 | 321.34 | 308.79 | 283.48 | 278.60 |
For the Biotechnology subindustry, Poseida Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Poseida Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Poseida Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $3.36 | * | 95.637 | |
= | $321.3 |
Poseida Therapeutics's Market Cap for the quarter that ended in Sep. 2024 is calculated as
Market Cap (Q: Sep. 2024 ) | = | Share Price (Q: Sep. 2024 ) | * | Shares Outstanding (EOP) (Q: Sep. 2024 ) |
= | $2.86 | * | 97.412 | |
= | $278.6 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poseida Therapeutics (NAS:PSTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Poseida Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark J Gergen | director, officer: President and CBO | C/O MIRATI THERAPEUTICS INC., 9393 TOWN CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Luke Corning | director | 614 DAVIS STREET, EVANSTON IL 60201 |
Marcea Bland Lloyd | director | 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Charles M Baum | director | C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
Cynthia Collins | director | 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
Rafael Amado | director | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Kristin Yarema | officer: President, Cell Therapy | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Malin Life Sciences Holdings Ltd | 10 percent owner | 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ---- |
Eric Ostertag | director, 10 percent owner, officer: Chief Executive Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Kerry D. Ingalls | officer: Chief Operating Officer | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brent Warner | officer: President, Gene Therapy | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Matthew A. Spear | officer: Chief Medical Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Harry J Leonhardt | officer: GC & Chief Compliance Officer | C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121 |
David Hirsch | director | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
From GuruFocus
By PRNewswire • 09-16-2024
By PRNewswire • 10-17-2024
By PRNewswire • 08-29-2024
By PRNewswire • 11-05-2024
By PRNewswire • 09-04-2024
By Business Wire • 11-28-2024
By PRNewswire • 11-14-2024
By PRNewswire • 11-26-2024
By GuruFocus News • 11-26-2024
By Marketwired • 12-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.